Palantir $11.2 Billion Revenue Backlog: Buy for 2026?
Palantir has a large revenue backlog, a major Army contract on the books, and ambitious growth guidance. This analysi...
Explore the best cash back cards that can help you maximize your savings on daily purchases. Start earning rewards effortlessly!
25,314 articlesPalantir has a large revenue backlog, a major Army contract on the books, and ambitious growth guidance. This analysi...
In March 2026, the drug stock landscape blends steady demand with ongoing innovation. This article highlights three c...
March brings renewed focus on artificial intelligence (ai) stocks as growth drivers focus on real products and predic...
FedEx reports earnings Tuesday, and traders want a clear take on demand, costs, and guidance. This guide breaks down ...
Pan American Silver readies for Q4 results as the precious metals retreat sets a challenging macro backdrop. The comp...
With Ford shares pressed lower by EV doubts and recalls, investors are weighing whether a cheap price reflects a dura...
An investor's guide to the early signals from hims 2026 earnings. We break down Q1 results, margins, and what they me...
A major fund recently shed about $20 million worth of Graphic Packaging shares, prompting questions about the company...
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
When CODA reports its Q2 2026 results, the focus shifts from headlines to signals—backlog, margins, and customer wins...
A booming demand backdrop for chips collides with sky-high spending. This piece breaks down what Taiwan Semiconductor...
Investors often chase big biotech gains, but Viking Therapeutics stock really hinges on milestones and cash runway. T...